<DOC>
	<DOCNO>NCT00606515</DOCNO>
	<brief_summary>The purpose study determine whether difference pharmacokinetics two taxane formulation , paclitaxel injection liposomal paclitaxel Chinese cancer patient solid tumor .</brief_summary>
	<brief_title>Pharmacokinetics Study Liposomal Paclitaxel Humans</brief_title>
	<detailed_description>The pharmacokinetics new formulation taxane ( liposomal paclitaxel ) never study Chinese cancer patient . This clinical trial design find pharmacokinetics liposomal paclitaxel dose 175mg/m2 whether different pharmacokinetic profile paclitaxel .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Eligible patient must histologically confirm solid tumor advance stage Patients suitable treat liposomal paclitaxel Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 Patients expect alive least 3 month Adequate hematologic , hepatic renal function Adequate organ function define protocol No prior systemic chemotherapy least 4 week recruitment No previous anaphylactic reaction hormone . Allergy study medication Serious complication would compromise patient 's ability complete study Grade â‰¥1 neuropathy use NCI CTCAE version 3.0 criterion Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Liposomal paclitaxel</keyword>
</DOC>